tirzepatide and palpitations Does Shrink Your Heart? Evidence Safety Facts GLP-1–Based Drug Tirzepatide Reduces Heart

Real-time fluorescence quantification Total RNA was extracted from kidney and intestinal tissues, as well as HK-2 and HIEC-6 cells, using the Trizol method (Invitrogen, USA)

Participants receiving retatrutide lost an average of 11.5% and as much as 16.8% of their body weight after 40 weeks, far exceeding the placebo groups 2.6% reduction

This approach allows each site approximately four weeks to recover between injections

doi:10.1123/ijspp.2023-0018

Retatrutide shares those GLP-1/GIP-related considerations and adds glucagon-specific ones

But, treatment should be accompanied by healthy habits, including a nutritious diet and regular physical activity, to achieve similar results